15 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
), is regulated under the Risk Evaluation and Mitigation Strategy (REMS) program to ensure safe use:
Healthcare Setting Administration: Esketamine must … be administered in a certified healthcare setting under the supervision of a healthcare provider.
Patient Monitoring: Patients must be monitored for at least
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
, WITHOUT LIMITATION, ANY WARRANTY OF TITLE, OR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
12.10 Healthcare Compliance. The Parties specifically
8-K
EX-99.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
in healthcare. As a leading innovator, they are committed to advancing the field by introducing groundbreaking solutions that cater to unaddressed
8-K
EX-1.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
of the Social Security Act) and all other government funded or sponsored healthcare programs, the Health Insurance Portability and Accountability Act
424B4
86z6 274qa
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
xc331
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
wrdch5g 8w3u
29 Jun 23
IPO registration
4:39pm
DRS/A
hck 24bmj0g6b
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
1x18ytcf4
2 May 23
Draft registration statement (amended)
12:00am
DRS
10diyv
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next